Century Therapeutics (IPSC) CEO reports 13,849-share tax withholding on RSU vesting

Rhea-AI Filing Summary

Century Therapeutics, Inc. President and CEO Brent Pfeiffenberger reported a tax-related share disposition. On the vesting of restricted stock units, the company withheld 13,849 shares of Common Stock at $2.24 per share to satisfy tax withholding obligations. This was not an open-market sale, and Pfeiffenberger continues to hold 3,665,474 shares of Common Stock directly after the transaction.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Pfeiffenberger Brent

Role President and CEO

Type	Security	Shares	Price	Value
Tax Withholding	Common Stock	13,849	$2.24	$31K

Holdings After Transaction: Common Stock — 3,665,474 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Shares withheld for taxes: 13,849 shares Implied share value for withholding: $2.24 per share Shares held after transaction: 3,665,474 shares

3 metrics

Shares withheld for taxes 13,849 shares Withheld to satisfy tax obligations on RSU vesting

Implied share value for withholding $2.24 per share Value associated with withheld Common Stock shares

Shares held after transaction 3,665,474 shares Common Stock directly owned by CEO after withholding

Key Terms

restricted stock units, tax withholding obligations, Common Stock, Form 4

4 terms

restricted stock units financial

"in connection with the vesting of restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax withholding obligations financial

"withheld by the Issuer to satisfy tax withholding obligations"

Common Stock financial

"security_title: "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Form 4 regulatory

"INSIDER FILING DATA (Form 4)"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pfeiffenberger Brent

(Last) (First) (Middle)

C/O CENTURY THERAPEUTICS, INC.

25 N 38TH STREET, 12TH FLOOR

(Street)

PHILADELPHIA PENNSYLVANIA 19104

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Century Therapeutics, Inc. [ IPSC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/11/2026		F(1)		13,849	D	$2.24	3,665,474	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units.

	/s/ Douglas Carr, Attorney-in-Fact	06/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Century Therapeutics (IPSC) report for its CEO?

Century Therapeutics reported that CEO Brent Pfeiffenberger had 13,849 shares of Common Stock withheld to cover taxes on vested restricted stock units. This tax-withholding disposition was reported on Form 4 and did not involve an open-market stock sale.

How many Century Therapeutics (IPSC) shares were withheld for taxes in this Form 4?

The Form 4 shows 13,849 shares of Century Therapeutics Common Stock were withheld at $2.24 per share. These shares satisfied tax withholding obligations arising from the vesting of restricted stock units, rather than being sold in the open market.

Does the Century Therapeutics (IPSC) CEO still hold shares after this tax withholding?

Yes. After the tax-withholding disposition, CEO Brent Pfeiffenberger directly holds 3,665,474 shares of Century Therapeutics Common Stock. The reported transaction only reflects shares withheld by the company for taxes tied to restricted stock unit vesting.

Was the Century Therapeutics (IPSC) insider transaction an open-market sale?

No. The transaction was coded as a tax-withholding disposition, meaning shares were withheld by Century Therapeutics to cover tax obligations. It did not represent an open-market sale or discretionary trade by CEO Brent Pfeiffenberger.

What price per share is associated with the Century Therapeutics (IPSC) tax-withholding shares?

The withheld shares are associated with a value of $2.24 per share. This figure appears in the Form 4 for the 13,849 shares withheld to satisfy tax withholding obligations upon vesting of restricted stock units for the CEO.